Xelor

Quick links to important sections

Xelor

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xelor

What is Xelor? (Latanoprost)

Property Description
Active Ingredient Latanoprost
Form Ophthalmic solution (Eye drops)
Pharmacological Class Prostaglandin Analogue, Ocular Hypotensive Agent
General Purpose Reduction of elevated intraocular pressure (IOP)
Origin Synthetic compound (Prodrug)

Xelor is a prescription-only ophthalmic solution used topically to reduce pressure inside the eye. The active substance in Xelor is Latanoprost (INN), a synthetic compound specifically developed as an ocular hypotensive agent. This medicine is classified as a prostaglandin analogue, a class of therapy clinically recognized for its effectiveness in managing elevated intraocular pressure.


What Type of Medicine is Xelor (Latanoprost)?

Xelor is an ocular hypotensive agent belonging to the prostaglandin analogue pharmacological class. This means its mechanism is modeled after naturally occurring fatty acid compounds but is synthesized in a laboratory to specifically target eye pressure. Prostaglandin analogues are a primary option for lowering elevated intraocular pressure, an established role for pressure management in adult patients.

Latanoprost is chemically structured as an isopropyl ester prodrug, a characteristic that allows the compound to be readily absorbed through the cornea and then converted into its biologically active acid form within the eye. This targeted chemical design distinguishes it from earlier agents and demonstrates high specificity for ocular tissue.


The Composition and Form of Xelor Eye Drops

The medicinal preparation is a single-ingredient product formulated as a sterile aqueous solution designed exclusively for topical administration to the eye. The form of eye drops is essential because it allows for direct and precise delivery of the Latanoprost to the ocular surface, minimizing systemic exposure while maximizing the local concentration where it is needed. The medication is prepared as an ophthalmic solution for lowering eye pressure, serving as a liquid, topical preparation designed for direct application to the eye surface, a key feature in its use scenario.


General Purpose and Mechanism of Action Summary

The overarching general purpose of Xelor is the reduction of elevated intraocular pressure (IOP). The primary action of this prostaglandin F₂ₐ analogue involves binding to specific receptors, which in turn facilitates the enhanced fluid outflow of the eye's aqueous humor. By targeting and increasing drainage through the unconventional uveoscleral pathway, Xelor effectively lowers the fluid volume and pressure within the eyeball, achieving the fundamental objective of an ocular hypotensive agent. This action provides a pathway for sustained management of pressure, typically as part of a once-daily regimen.

Regulatory References

  1. NIH/NLM Drug Information Portal
  2. MedlinePlus

What side effects are possible with Xelor?

Possible side effects and safety information

The safety profile of Xelor (Capecitabine) is characterized by specific officially documented adverse reactions, categorized by frequency and affected body systems as established by regulatory authorities.


Key Adverse Reaction Classifications

The most frequently observed adverse reactions, officially classified as Very Common, primarily involve the gastrointestinal system and skin. This category includes severe Diarrhea, Nausea, Vomiting, Stomatitis (mouth soreness), and the specific skin reaction known as Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia). Other frequent reactions include fatigue and weakness (asthenia).

Reactions classified as Common include dehydration, hair loss (alopecia), headache, dizziness, and mild hematological changes such as anemia and neutropenia.


Serious Adverse Reactions and Safety Constraints

The official labeling documents potential serious risks, including life-threatening Severe Diarrhea and Dehydration, clinically significant Myelosuppression (severe blood cell suppression), and Cardiotoxicity (such as myocardial infarction or angina). The profile is structurally defined by these risks and requires specific monitoring of complete blood counts and liver function tests.

Safety Restrictions: The medicine is formally contraindicated in patients with a known Dihydropyrimidine Dehydrogenase (DPD) deficiency due to the high risk of severe toxicity. Population-specific safety considerations require careful monitoring of patients with mild to moderate hepatic impairment, and dose modification or avoidance in cases of moderate to severe renal impairment. Furthermore, regulatory data indicates that older adults may experience a higher incidence of Grade 3 and 4 adverse reactions, including Hand-Foot Syndrome.

Overdose and Emergency Response

Overdose with Xelor (Capecitabine) may result in an immediate and significant exaggeration of the known toxicities, which can lead to severe or life-threatening systemic effects. The overdose profile is defined by the manifestation of severe gastrointestinal toxicity, including persistent diarrhea, vomiting, and debilitating stomatitis (mucositis). Acute high-level exposure also carries a significant risk of profound myelosuppression, leading to conditions such as severe neutropenia and anemia.

Feature Official Regulatory Statement
Severity classification Risk of severe and potentially fatal toxicities.
Population-specific notes Patients with complete DPD deficiency face an increased risk for acute, early-onset, severe, or fatal adverse reactions. The antidote is approved for use in pediatric patients.
Emergency-response Seek immediate medical attention and contact emergency services upon suspected or confirmed overdose.

Official regulatory documents mandate that the specific antidote, uridine triacetate, is the required emergency treatment for adult and pediatric patients following an overdose. Treatment must be initiated as soon as possible and ideally within a defined time frame following exposure to mitigate the toxic effects. Management also requires close medical monitoring in a hospital setting and supportive care to correct complications such as dehydration and electrolyte imbalance.

Therapeutic Uses of Xelor

What Xelor Treats: Main Uses and Benefits

The medication Xelor, a formulation of the active ingredient capecitabine, is commonly used for managing conditions in the therapeutic domain of oncology. This treatment is applied across domains where additional symptomatic support is needed and may be part of symptomatic management in patients with certain advanced cancers. It is indicated for conditions presenting with acute episodes and significant symptomatic burden, such as metastatic colorectal cancer, advanced or metastatic breast cancer, and is considered relevant in contexts involving heightened systemic burden.


The main uses of this treatment contribute to easing the overall symptom load. It helps address symptom clusters related to tumors that interfere with daily functioning, and it is relevant in clinical settings that involve acute or unstable symptom patterns. The treatment provides support that helps ease the overall symptom burden. It assists with maintaining functional stability and general well-being during symptomatic phases, and is considered relevant in contexts involving heightened systemic burden.

Quick Fact: May assist with symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Who can and cannot use Xelor (Latanoprost)?

Eligibility for Xelor, an ophthalmic solution containing Latanoprost, is determined by specific population and health status criteria documented in regulatory prescribing information, such as the FDA Prescribing Information.


Populations Strictly Contraindicated

Xelor must not be used in patients with a known hypersensitivity or allergy to Latanoprost or any other component in the eye drop formulation.

Age-Related Eligibility

  • Adults: The medicine is approved for use in adult patients.
  • Pediatric Use: The safety and effectiveness have not been established in children and adolescents, meaning use is generally not recommended for this age group.
  • Older Adults: Use is acceptable; clinical trials showed no overall differences in safety or effectiveness compared to younger adults.

Restricted or Conditional Use

Use of Xelor requires special caution or is restricted in several situations:

  • Ocular Inflammation: Use should be avoided in cases of active iritis or uveitis, and active Herpes Simplex Keratitis, as there is a risk of exacerbation.
  • Pregnancy and Lactation: Use during pregnancy is generally restricted to when the potential benefit outweighs the potential risk. For breastfeeding women, a decision must be made to discontinue nursing or discontinue the drug, as its presence in human milk is not confirmed.
  • Concomitant Use: It is not recommended to use Xelor simultaneously with two or more other prostaglandin analogs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Xelor (Latanoprost) is specifically defined by its localized action as an ophthalmic solution with minimal systemic exposure. The regulatory documentation primarily focuses on interactions with other eye medications and mandatory administration rules, while noting an absence of documented systemic interactions.


Documented Pharmacodynamic Interactions

Co-administration with other prostaglandin analogues (ophthalmic solutions) is not recommended by regulatory authorities. This restriction is due to a documented pharmacodynamic interaction that results in a paradoxical elevation in intraocular pressure (IOP), counteracting the intended therapeutic effect of lowering eye pressure.


Administration Timing and Procedural Constraints

Official labels mandate strict timing rules for co-administering Xelor with other topical medications. When using Xelor with any other topical ophthalmic drug product, the products must be administered at least five (5) minutes apart. Furthermore, this five-minute separation is specifically required for eye drops that contain thimerosal to prevent in vitro physical precipitation of the active ingredient.


Systemic Interaction Status

Due to Xelor’s rapid local metabolism and negligible systemic concentration, regulatory documents state that there are no known clinically significant systemic interactions documented with CYP enzymes, transporters, food, alcohol, or herbal products.

Mechanism of Action

Prostanoid Receptor Activation and Initial Signaling

Xelor's active form, Latanoprost acid, functions as a selective agonist for the Prostanoid FP Receptor in the ciliary muscle. This receptor-mediated activation initiates a core molecular cascade that results in extracellular matrix alteration.


Extracellular Matrix Alteration and Tissue Permeability

The initial signaling cascade leads to the increased activity of Matrix Metalloproteinases (MMPs). These enzymes degrade and reorganize the extracellular matrix (connective tissue) of the ciliary muscle, resulting in increased spaces between the muscle bundles. This modification causes the relaxation of the muscle and an enhancement of the tissue’s permeability.


Enhanced Uveoscleral Outflow Dynamics

The relaxed and more permeable ciliary muscle facilitates a significant increase in the drainage of aqueous humor through the uveoscleral outflow pathway. This acceleration of fluid exit is the functional consequence of the mechanism, leading to a reduction of intraocular fluid volume and pressure.


Mechanistic Limitation

Administering Xelor more than once daily can saturate or desensitize the FP receptors. This can lead to a reduced pressure-lowering effect or, in some cases, a paradoxical increase in intraocular pressure, constraining the frequency of receptor engagement.

Dosage and Administration Information

How to Use Xelor (Cefaclor Granules for Oral Suspension) — Administration Guidelines

This section outlines instructions for the correct administration of Xelor (Cefaclor Granules for Oral Suspension).


Administration Scope

Instruction Guideline
Route of Administration Oral administration only.
Timing in relation to Meals May be administered with or without food.
Course Duration Administer for a minimum of 10 days for certain streptococcal infections. Treatment should continue for at least 48 to 72 hours after symptoms subside or bacterial eradication is confirmed.

Dosing and Frequency

Population Standard Dosing Regimen
Adults The usual dosage is 250 mg every 8 hours. The dose may be doubled (up to 500 mg every 8 hours) for more severe infections, not to exceed a total of 4 g daily.
Pediatrics ( ge 1 month) 20 mg/kg/day in divided doses, typically every 8 hours. For serious infections, the dose is 40 mg/kg/day. Safety and efficacy are not established for infants under one month of age.

Preparation and Procedural Steps

The granules must be reconstituted before use to form the oral suspension. This involves adding the specified amount of water to the bottle in two portions, capping it, and shaking well immediately. The suspension must be shaken well before each use. Dosage must be measured accurately using a calibrated measuring device. Once reconstituted, the suspension must be stored in a refrigerator (2–8°C) and discarded after 14 days to maintain stability.

Connection to the Use Protocol

The protocol dictates a precise sequence of preparation, accurate measurement, and adherence to a fixed dosing schedule. The initial reconstitution ensures the correct drug concentration, while the requirement to shake well before each use and measure with a calibrated device ensures the patient receives the exact prescribed dose at the designated 8-hour or 12-hour intervals for the full treatment duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xelor (Latanoprost)

The research landscape for Xelor (Latanoprost) focuses primarily on its use as a medicine applied to the eye to study Intraocular Pressure (IOP). The available evidence comes mainly from official regulatory submissions and subsequent scientific reviews, which draw upon clinical trials. The research describes the study patterns and observed outcomes across the different patient groups where Xelor was evaluated in.


Evidence for use in Primary Open-Angle Glaucoma and Ocular Hypertension

For these common eye pressure conditions, Xelor was studied for how it affects the pressure inside the eye, which is known as Intraocular Pressure (IOP). The research base for this use includes numerous Randomized Controlled Trials (RCTs). These trials are a key study type for evaluating medicines and often compared Xelor against a placebo or against other ophthalmic agents such as Timolol. The main focus of these studies was the monitoring of IOP measurements from the start of the study.

The findings derived from these large-scale studies and subsequent meta-analyses indicate patterns related to IOP measurements in adults. Research describes IOP measurements over time compared to the initial levels. Studies also examined how Xelor compared to Timolol, often describing similar patterns of IOP measurements between the two treatments. This comprehensive evidence contributes to the broader evidence landscape for Intraocular Pressure (IOP).


Long-term Studies and Extended Follow-up

Initial clinical trials for Xelor often had follow-up durations that were limited to a few weeks or months. Following these initial evaluations, extended observational settings and open-label studies were conducted, which monitored patients for periods of up to five years. These longer studies research examined the extended patterns of the medicine's association with IOP measurements.


What is Still Uncertain in the Research Landscape for Xelor

Scientific reviews highlight several areas where evidence remains limited. First, while Xelor was studied for IOP change, the long-term data examining the functional clinical outcome—namely the preservation of visual fields and optic nerve health over many years—is not fully established through long-term, masked, placebo-controlled trials. Second, research for certain conditions like Chronic Angle-Closure Glaucoma or for special groups like pediatric patients was observed to have sample sizes that were modest and follow-up durations were limited.

Key Studies & References

  1. Latanoprost Ophthalmic: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Xelor (FAQ)


Q: How long does it usually take to see if Xelor is working?

Official product information suggests that the reduction in intraocular pressure (IOP) typically starts within three to four hours after applying the eye drops. The maximum intended pressure-lowering effect is generally observed eight to twelve hours after administration.


Q: Are there any restrictions for people with kidney problems using Xelor?

Regulatory documents indicate that the medicine has not been fully studied in patients with impaired kidney function. For this reason, official prescribing information notes that use of Xelor in this patient population is to be managed with caution.


Q: What happens if I miss a dose of Xelor?

The official instructions for a missed dose state that treatment should continue with the next scheduled dose as normal. It is specified that double or extra doses must not be used.


Q: Does Xelor have a generic version available?

Yes, Xelor’s active ingredient, Latanoprost, is widely available as a generic ophthalmic solution. This can be confirmed by reviewing official drug information or product databases.


Q: Is Xelor considered a controlled substance?

Xelor is classified as an ocular hypotensive agent and is available only by prescription. However, it is not listed as a federally controlled substance by regulatory authorities.


Q: Are there any warnings about Xelor and driving?

Official warnings state that Xelor may cause short-term disturbances in vision, such as blurring, immediately after application. If these vision changes occur, activities such as driving or operating machinery should be avoided until vision is clear.


Q: Can I use Xelor if I have heart disease?

Official post-marketing experience has reported some cardiac events, including angina (chest pain), unstable angina, and palpitations (irregular heartbeats). This information indicates that the presence of these cardiac reports may be a factor to be managed in patients with pre-existing heart conditions.


Q: Do I need to take Xelor at a specific time of day?

The official product instructions recommend one drop once daily. This dosing is noted to be preferably taken in the evening, as studies show the maximum intended effect on eye pressure is reached at night.


Q: Is Xelor effective for everyone who takes it?

Clinical trial summaries show that Xelor is associated with a mean reduction in intraocular pressure (IOP) of approximately 25% to 33% in patients studied over several months. While this pattern is strong, it is acknowledged that individual patient responses to the medicine may vary.


Q: Can Xelor affect birth control pills?

Official regulatory documents state that Xelor undergoes rapid local metabolism in the eye and has a negligible concentration in the systemic circulation (the bloodstream). For this reason, there are no known clinically significant systemic interactions documented with other oral medications, including birth control pills.


Q: Is there a maximum amount of time someone can take Xelor?

Studies indicate that the medicine can maintain a stable eye pressure-lowering effect for at least 24 months during prolonged treatment. However, the long-term effects related to certain changes, such as increased iris pigmentation, are not fully established beyond five years of use.


Q: How does taking Xelor affect daily routines?

Official warnings related to daily use focus on contact lenses. Soft contact lenses are to be removed from the eye prior to applying Xelor. They may be reinserted 15 minutes after the eye drops have been administered.


Q: What is the half-life of Xelor?

Pharmacokinetic data from official sources describes the very short elimination half-life of the active form of the drug (latanoprost acid) in the systemic circulation (blood plasma). This period is approximately 17 minutes.


Q: Does Xelor change how my liver works?

The active substance in Xelor is known to be metabolized by the liver. Official warnings state that Xelor has not been extensively studied in patients with impaired hepatic (liver) function.


Q: How does taking Xelor affect the color of my eyes?

Official warnings state that Xelor may gradually increase the amount of brown pigment in the iris, which is the colored part of the eye. This change can occur over months to years and is described as likely to be permanent, even if the treatment is stopped.


Q: How does Xelor compare to similar medicines for the same condition?

Clinical evidence describes Xelor’s ability to reduce intraocular pressure (IOP) compared to other medicines. In studies, Xelor demonstrated an IOP-lowering effect that was generally comparable to or greater than twice-daily Timolol 0.5%.


Q: Can Xelor cause long-term side effects?

One specific long-term effect is the potential for increased brown pigment in the iris. Official product information indicates this color change is likely to be permanent, even after the medicine is discontinued. Other changes affecting the skin around the eye and eyelashes are reported to be reversible in some patients.


Q: Why do doctors prescribe Xelor instead of other options?

Regulatory and clinical literature often position Xelor as a first-line therapy for open-angle glaucoma and ocular hypertension. This position is supported by its proven efficacy and the once-daily administration schedule, which is associated with promoting patient adherence.


Q: Can I stop taking Xelor once my symptoms improve?

The primary goal of this therapy is to continuously maintain a low target eye pressure. Official information indicates that the reduction in pressure is maintained with continued use of the medicine, and the pressure-lowering effect may last for about two weeks after the drug is stopped.


Q: Is Xelor taken short-term or long-term?

Xelor is typically used for the chronic management of open-angle glaucoma and ocular hypertension. Studies have shown the reduction in eye pressure is generally maintained for at least 24 months of therapy without the effect diminishing over time.


Q: Is Xelor used for more than one medical condition?

Yes, the official labeling and indications confirm Xelor is approved for reducing elevated intraocular pressure (IOP). Specifically, this includes patients diagnosed with both open-angle glaucoma and ocular hypertension.


Q: Why do some people experience nausea with Xelor?

Nausea is a side effect that has been reported in post-marketing experience with Xelor. While this occurrence is listed in official safety information, the exact clinical mechanism for this systemic reaction is not detailed in the product label.


Q: If I have mild side effects, is that normal when adjusting to Xelor?

The most common side effects observed in clinical trials, affecting 5% to 15% of patients, include eye redness, blurred vision, burning, stinging, and itching. Official product information describes these frequent occurrences but does not specify the typical duration of an adjustment period.


Q: What are the most serious possible side effects listed for Xelor?

Serious side effects listed in official safety documents include potentially permanent changes to the iris color, the development of macular edema, and inflammation inside the eye such as iritis or uveitis. There have also been reports of asthma exacerbation and corneal issues.


Q: What happens if I take Xelor twice in one day by accident?

Official instructions warn that the dosage must not exceed one application per day. Administering the medicine more frequently is not advised because it may actually lessen the intended eye pressure-lowering effect or, in some instances, cause a paradoxical increase in eye pressure.

How should Xelor be stored and disposed of?

Storage and Disposal of XELOR (Latanoprost Ophthalmic Solution)

Official regulations define strict storage and disposal requirements for XELOR eye drops to maintain stability and prevent contamination.

Mandatory Storage Conditions

  • Unopened bottles must be stored under refrigeration (2 C to 8 C).
  • The product must not be frozen at any time.
  • Store the bottle in its original outer carton to protect the solution from light.

In-Use Stability and Safety

  • Once the bottle is opened, the solution must be discarded after four weeks (one month), regardless of the expiration date or amount remaining.
  • Keep XELOR out of the sight and reach of children.

Disposal Instructions

  • Do not dispose of unused or expired medicine via wastewater or household trash.
  • Return the product to a pharmacist or an approved drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xelor found in:

A-Z Index: